JP2014512014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512014A5 JP2014512014A5 JP2014505335A JP2014505335A JP2014512014A5 JP 2014512014 A5 JP2014512014 A5 JP 2014512014A5 JP 2014505335 A JP2014505335 A JP 2014505335A JP 2014505335 A JP2014505335 A JP 2014505335A JP 2014512014 A5 JP2014512014 A5 JP 2014512014A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- biomarker
- agent
- filamin
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 40
- 208000011200 Kawasaki disease Diseases 0.000 claims description 26
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 26
- 102000013366 Filamin Human genes 0.000 claims description 23
- 108060002900 Filamin Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000010606 normalization Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 238000008157 ELISA kit Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 108091008147 housekeeping proteins Proteins 0.000 claims description 2
- 108090000265 Meprin A Proteins 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475936P | 2011-04-15 | 2011-04-15 | |
| US61/475,936 | 2011-04-15 | ||
| US201161579007P | 2011-12-22 | 2011-12-22 | |
| US61/579,007 | 2011-12-22 | ||
| PCT/US2012/033514 WO2012142409A2 (en) | 2011-04-15 | 2012-04-13 | Diagnostic markers and therapeutic targets of kawasaki disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512014A JP2014512014A (ja) | 2014-05-19 |
| JP2014512014A5 true JP2014512014A5 (cg-RX-API-DMAC7.html) | 2015-05-28 |
| JP6072768B2 JP6072768B2 (ja) | 2017-02-01 |
Family
ID=46208753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505335A Expired - Fee Related JP6072768B2 (ja) | 2011-04-15 | 2012-04-13 | 川崎病の診断マーカーおよび治療標的 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9869673B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3086121A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6072768B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140034193A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106053835A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012242684B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2833257A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012142409A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168602A2 (en) * | 2014-05-02 | 2015-11-05 | Momenta Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of kawasaki disease |
| CA2955214C (en) * | 2014-07-24 | 2023-03-21 | Academia Sinica | Diagnosis and treatment of kawasaki disease |
| KR102056405B1 (ko) * | 2018-04-05 | 2019-12-16 | (주)메디젠휴먼케어 | Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법 |
| CN110763845B (zh) * | 2018-07-27 | 2022-10-28 | 成都市第三人民医院 | 一种检测蛋白标志物的配体在制备用于诊断结肠癌的产品中的用途和试剂盒 |
| TWI704349B (zh) * | 2019-06-17 | 2020-09-11 | 高雄榮民總醫院 | 蛋白質生物標記用以診斷川崎症的用途 |
| JPWO2022071601A1 (cg-RX-API-DMAC7.html) * | 2020-10-02 | 2022-04-07 | ||
| CN113267626B (zh) * | 2021-05-17 | 2023-01-13 | 郑州大学第一附属医院 | 一种用于高危人群贲门腺癌早期筛查的试纸条 |
| KR102705469B1 (ko) * | 2022-05-30 | 2024-09-11 | 충남대학교산학협력단 | 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| WO2007003594A1 (en) * | 2005-07-01 | 2007-01-11 | Solvay Pharmaceuticals Gmbh | Screening methods for inhibitors of the metalloprotease meprin |
| JP4795037B2 (ja) | 2006-02-01 | 2011-10-19 | 財団法人 神戸市地域医療振興財団 | 川崎病の判定方法及びそのためのキット |
| WO2007142347A1 (ja) * | 2006-06-05 | 2007-12-13 | Shimadzu Corporation | 腫瘍マーカー及び癌疾病の罹患の識別方法 |
| AU2007284651B2 (en) * | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| US20090093005A1 (en) * | 2007-10-05 | 2009-04-09 | University Of Virginia Patent Foundation | Protein-based biomarkers for abdominal aortic aneurysm |
| WO2010099918A1 (en) * | 2009-03-06 | 2010-09-10 | Klaus Tschira Stiftung Ggmbh | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
-
2012
- 2012-04-13 CN CN201610498798.6A patent/CN106053835A/zh active Pending
- 2012-04-13 JP JP2014505335A patent/JP6072768B2/ja not_active Expired - Fee Related
- 2012-04-13 AU AU2012242684A patent/AU2012242684B2/en not_active Expired - Fee Related
- 2012-04-13 CN CN201280024575.6A patent/CN103562725B/zh not_active Expired - Fee Related
- 2012-04-13 KR KR1020137030334A patent/KR20140034193A/ko not_active Withdrawn
- 2012-04-13 WO PCT/US2012/033514 patent/WO2012142409A2/en not_active Ceased
- 2012-04-13 EP EP16162648.6A patent/EP3086121A1/en not_active Withdrawn
- 2012-04-13 EP EP12725900.0A patent/EP2697653B1/en not_active Not-in-force
- 2012-04-13 US US14/111,816 patent/US9869673B2/en not_active Expired - Fee Related
- 2012-04-13 CA CA2833257A patent/CA2833257A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512014A5 (cg-RX-API-DMAC7.html) | ||
| Martinez et al. | The diagnosis of idiopathic pulmonary fibrosis: current and future approaches | |
| Ray et al. | Statistical evaluation of a biomarker | |
| Verstraete et al. | TDP-43 plasma levels are higher in amyotrophic lateral sclerosis | |
| Saenger et al. | Requiem for a heavyweight: the demise of creatine kinase-MB | |
| Han et al. | Red blood cell distribution width predicts long-term outcomes in sepsis patients admitted to the intensive care unit | |
| Yang et al. | Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature | |
| JP2014508298A5 (cg-RX-API-DMAC7.html) | ||
| ES2686135T3 (es) | Sistema y método para determinar el riesgo de diabetes sobre la base de análisis de marcador bioquímico | |
| Purrucker et al. | Serum protein S100β is a diagnostic biomarker for distinguishing posterior circulation stroke from vertigo of nonvascular causes | |
| JP2018529931A5 (cg-RX-API-DMAC7.html) | ||
| Liang et al. | Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis | |
| McFalls et al. | Outcomes of hospitalized patients with non-acute coronary syndrome and elevated cardiac troponin level | |
| JP2020514689A5 (cg-RX-API-DMAC7.html) | ||
| Franco-Marina et al. | Efficient screening for COPD using three steps: a cross-sectional study in Mexico City | |
| Cappellini et al. | Heart-type fatty acid-binding protein may exclude acute myocardial infarction on admission to emergency department for chest pain | |
| Morakami et al. | Can the six-minute walk distance predict the occurrence of acute exacerbations of COPD in patients in Brazil? | |
| Blasi et al. | The role of biomarkers in low respiratory tract infections | |
| Arora et al. | Does serum procalcitonin aid in the diagnosis of bloodstream infection regardless of whether patients exhibit the systemic inflammatory response syndrome? | |
| Aydemir et al. | Does new onset and pre-existing atrial fibrillation predict mortality in COVID-19 patients? | |
| Lo et al. | Ineffective esophageal motility is associated with acute rejection after lung transplantation independent of gastroesophageal reflux | |
| Meiner et al. | Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel | |
| Thway et al. | Evaluating the impact of matrix effects on biomarker assay sensitivity | |
| Alquezar-Arbe et al. | Cardiac troponins: 25 years on the stage and still improving their clinical value | |
| El-Khoury et al. | Longitudinal assessment of SARS-CoV-2 antinucleocapsid and antispike-1-RBD antibody testing following PCR-detected SARS-CoV-2 infection |